Teams
-
-
Christine Bodemer
>> Reference Center for rare diseases
Genetic skin disorders (MAGEC)
Associated with the French Healthcare Network FIMARAD and the European Reference Network (ENR) SKIN
Imagine's Offers
-
Cutis laxaGenotype PhenotypeTargetsTherapeuticsClinical trialsEhlers-Danlos syndromeGenotype PhenotypeTargetsTherapeuticsClinical trialsAtopic dermatitisGenotype PhenotypeTargetsTherapeuticsClinical trials
-
Epidermolysis bullosa
Recessive Dystrophic Epidermolysis bullosa (RDEB)Genotype PhenotypeTargetsTherapeuticsClinical trialsJunctional Epidermolysis Bullosa (JEB)Genotype PhenotypeTargetsTherapeuticsClinical trialsEpidermolysis bullosa simplex (EBS)Genotype PhenotypeTargetsTherapeuticsClinical trialsIchthyosis
Netherton syndrome (NS)Genotype PhenotypeTargetsTherapeuticsClinical trialsLamellar ichthyosisGenotype PhenotypeTargetsTherapeuticsClinical trialsNonbullous congenital ichthyosiform erythroderma (NBCIE)Genotype PhenotypeTargetsTherapeuticsClinical trialsOther epidermal disorders
Darier diseaseGenotype PhenotypeTargetsTherapeuticsClinical trialsEctodermal dysplasiaGenotype PhenotypeTargetsTherapeuticsClinical trialsPalmoplantar keratodermaGenotype PhenotypeTargetsTherapeuticsClinical trialsFamilial Benign Chronic Pemphigus (Hailey-Hailey Disease)Genotype PhenotypeTargetsTherapeuticsClinical trials -
Chronic Granulomatous disease (CGD)Genotype PhenotypeTargetsTherapeuticsClinical trialsWiskott-Aldrich syndrome (WAS)Genotype PhenotypeTargetsTherapeuticsClinical trialsSAMEC syndromeGenotype PhenotypeTargetsTherapeuticsClinical trialsEpidermodysplasia verruciformisGenotype PhenotypeTargetsTherapeuticsClinical trials
-
For further information, please contact us!
PhotodermatosisGenotype PhenotypeTargetsTherapeuticsClinical trialsPigmentation anomaly of the skinGenotype PhenotypeTargetsTherapeuticsClinical trialsSubcutaneous tissue disorderGenotype PhenotypeTargetsTherapeuticsClinical trialsUrticariaGenotype PhenotypeTargetsTherapeuticsClinical trials
Contacts
-
Thibaut PERCHET
Business development manager
- thibaut.perchet@institutimagine.org
- +33(0)1 42 75 42 55